PACB - Pacific Biosciences of California Stock Price, Fair Value and News

2.13USD+0.22 (+11.52%)Market Closed

Market Summary

USD2.13+0.22

Market Closed

11.52%

PACB Stock Price

View Fullscreen

PACB RSI Chart

PACB Valuation

Market Cap

580.1M

Price/Earnings (Trailing)

-1.95

Price/Sales (Trailing)

2.89

EV/EBITDA

-1.79

Price/Free Cashflow

-2.33

PACB Price/Sales (Trailing)

PACB Profitability

Operating Margin

27.09%

EBT Margin

-153.83%

Return on Equity

-45.75%

Return on Assets

-17.78%

Free Cashflow Yield

-42.95%

PACB Fundamentals

PACB Revenue

Revenue (TTM)

200.4M

Rev. Growth (Yr)

-0.23%

Rev. Growth (Qtr)

-33.5%

PACB Earnings

Earnings (TTM)

-296.9M

Earnings Growth (Yr)

11.18%

Earnings Growth (Qtr)

4.68%

Breaking Down PACB Revenue

Last 7 days

28.3%

Last 30 days

56.6%

Last 90 days

44.9%

Trailing 12 Months

-83.9%

How does PACB drawdown profile look like?

PACB Financial Health

Current Ratio

9.28

Debt/Equity

Debt/Cashflow

-93.63

PACB Investor Care

Shares Dilution (1Y)

8.99%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	200.4M	0	0	0
2023	134.0M	146.1M	169.5M	200.5M
2022	134.7M	139.5M	137.0M	128.3M
2021	92.3M	105.8M	121.6M	130.5M
2020	90.1M	82.5M	79.7M	78.9M
2019	75.7M	78.7M	82.5M	90.9M
2018	87.9M	89.4M	84.0M	78.6M
2017	96.5M	95.8M	94.3M	93.5M
2016	94.3M	90.1M	101.3M	90.7M
2015	66.6M	80.1M	73.4M	92.8M
2014	34.2M	39.6M	52.8M	60.6M
2013	21.5M	20.3M	24.9M	28.2M
2012	43.6M	40.3M	32.5M	26.0M
2011	9.7M	17.8M	25.8M	33.9M
2010	0	648.0K	1.2M	1.7M
2009	0	0	0	135.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

CEO	Mr. Christian O. Henry M.B.A.
WEBSITE	pacb.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	769

Pacific Biosciences of California Frequently Asked Questions

What is the ticker symbol for Pacific Biosciences of California? What does PACB stand for in stocks?

PACB is the stock ticker symbol of Pacific Biosciences of California. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pacific Biosciences of California (PACB)?

As of Fri Jul 26 2024, market cap of Pacific Biosciences of California is 580.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PACB stock?

You can check PACB's fair value in chart for subscribers.

Is Pacific Biosciences of California a good stock to buy?

The fair value guage provides a quick view whether PACB is over valued or under valued. Whether Pacific Biosciences of California is cheap or expensive depends on the assumptions which impact Pacific Biosciences of California's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PACB.

What is Pacific Biosciences of California's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, PACB's PE ratio (Price to Earnings) is -1.95 and Price to Sales (PS) ratio is 2.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PACB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pacific Biosciences of California's stock?

In the past 10 years, Pacific Biosciences of California has provided -0.079 (multiply by 100 for percentage) rate of return.